Alphatec (ATEC) to Release Earnings on Tuesday

Alphatec (NASDAQ:ATEC) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Alphatec to post earnings of ($0.33) per share for the quarter. Alphatec has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The firm had revenue of $138.00 million for the quarter, compared to the consensus estimate of $131.90 million. The firm’s revenue was up 30.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.33) EPS. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Trading Up 3.3 %

Alphatec stock opened at $13.65 on Monday. Alphatec has a 52 week low of $8.66 and a 52 week high of $19.14. The company has a debt-to-equity ratio of 6.54, a quick ratio of 1.99 and a current ratio of 2.86. The firm has a market capitalization of $1.91 billion, a PE ratio of -8.81 and a beta of 1.48. The business’s 50-day simple moving average is $13.39 and its 200-day simple moving average is $13.54.

Insider Buying and Selling

In other news, EVP David Sponsel sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total transaction of $40,400.00. Following the completion of the sale, the executive vice president now owns 637,418 shares in the company, valued at $10,300,674.88. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP David Sponsel sold 2,500 shares of Alphatec stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $16.16, for a total value of $40,400.00. Following the transaction, the executive vice president now directly owns 637,418 shares of the company’s stock, valued at $10,300,674.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Todd Koning sold 121,601 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $1,617,293.30. Following the transaction, the chief financial officer now directly owns 430,856 shares of the company’s stock, valued at approximately $5,730,384.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 285,069 shares of company stock valued at $3,971,495. 29.12% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price objective on shares of Alphatec in a research report on Wednesday, March 20th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, March 4th. Wells Fargo & Company assumed coverage on shares of Alphatec in a research report on Friday, February 9th. They set an “overweight” rating and a $26.00 target price on the stock. Finally, Needham & Company LLC increased their price target on shares of Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.63.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.